FDA Challenges Efficacy of Investigational Drug Candidates

The FDA has raised significant concerns about the efficacy of multiple investigational drug candidates ahead of regulatory hearings and meetings. The agency has questioned whether Capricor's deramiocel stem cell treatment for Duchenne muscular dystrophy and Replimune's RP1 skin cancer treatment met their primary trial endpoints or demonstrated sufficient clinical benefit for approval.

This is a long-running storyline that has developed over 9 days. The homepage highlights its most recent activity, so the outlet count there reflects the latest wave. The totals above cover the full run.